Alphadi Soft Capsules (Alfacalcidol)

Adult dose

Chronic renal failure and osteoporosis: Administer 0.5–1 µg of alfacalcidol once daily orally. Hypoparathyroidism and other conditions related to vitamin D metabolism abnormalities: Administer 1–4 µg of this medicine once daily orally.

Child dose

Osteoporosis: Administer 0.01–0.03 µg of alfacalcidol per kg of body weight once daily orally. Other conditions: Administer 0.05–0.1 µg of this medicine per kg of body weight once daily orally.

This medicine should not be taken by individuals with certain conditions such as hypercalcemia, hyperphosphatemia, and hypermagnesemia. Additionally, it should be avoided in cases where the product of calcium and phosphate in the blood exceeds a certain value or in cases of alkalosis. Individuals suspecting vitamin D toxicity or those with allergies to ingredients contained in this medication should also refrain from taking it. While taking this medicine, it is important not to take it concurrently with magnesium-containing preparations, vitamin D and its derivatives, calcium-containing preparations, or certain diuretics. Concurrent use with these medications increases the likelihood of side effects such as hypercalcemia or hypermagnesemia. Women who are breastfeeding are advised to avoid taking this medicine because its safety has not been established; if unavoidable, it is advisable to stop breastfeeding. Pregnant women or those who may become pregnant should take this medicine only after sufficient consultation with a doctor, as overdose may be toxic to the fetus. Children, the elderly, patients taking certain medications, and those with kidney stones or sarcoidosis must consult a healthcare professional before taking this medicine. While taking this medicine, symptoms related to hypercalcemia, such as gastrointestinal disturbances, neurological symptoms, heart issues, kidney function decline, liver function abnormalities, skin rashes, eye problems, and skeletal pain may occur. If these symptoms appear, the medicine should be stopped immediately, and a healthcare professional must be consulted. Regular monitoring of serum calcium levels is essential to prevent overdose, and patients with hyperphosphatemia may require additional treatment to control phosphate levels. In case of overdose, immediately discontinue use and receive appropriate emergency care, and dosage can be adjusted for resumption only after restoring serum calcium levels to the normal range. Keep this medication out of reach of children, store in a cool, dry place, away from direct sunlight, and ensure it is tightly sealed. Also, do not transfer to another container and be cautious to prevent misuse.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with high fever, blisters, skin peeling, pain in mucous membranes of the mouth/eyes, shortness of breath or difficulty breathing, asthma attacks, respiratory problems accompanied by coughing and fever, jaundice (yellowing of skin or eyes), extreme lethargy, sudden and severe headaches, thunderclap headache, seizures, confusion, visual disturbances, paralysis, etc.

Mild side effects

• Loss of appetite
• nausea
• vomiting
• diarrhea
• constipation
• stomachache
• discomfort in the upper abdomen
• abdominal bloating
• indigestion
• thirst

Drug interactions

This medication should not be taken concurrently with vitamin D and its derivatives, thiazide diuretics, digitalis, resins such as cholestyramine, mineral oil, phenytoin, glucocorticoids, colestipol, sucralfate, aluminum-containing antacids, estrogens (ethinyl estradiol, norethisterone), barbiturates, and antiepileptic drugs without consulting a physician or pharmacist.

Food interactions

Do not take this medicine concurrently with magnesium-containing or calcium-containing products.

This medicine should be stored in a tightly sealed container to prevent air or moisture ingress. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius. This will help preserve the effectiveness of the medicine for a longer duration.

Appearance

Transparent brown oval-shaped soft capsules containing a colorless to pale yellow transparent oily substance

Package unit

240 capsules/box [10 capsules/PTP X 24], 60 capsules/box [10 capsules/PTP X 6]